DORIS ANUKAM: Open Payments
NPI 1952637795 · RENO, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$540 in 12 payments from 8 companies in 2025. Trend: 2023 $1,315 · 2024 $2,333 · 2025 $540
Food & beverage: $541
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 2 | $147 |
| Otsuka America Pharmaceutical, Inc. | 1 | $122 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $118 |
| ABBVIE INC. | 3 | $68 |
| Alkermes, Inc. | 1 | $25 |
| E.R. Squibb & Sons, L.L.C. | 1 | $25 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Vanda Pharmaceuticals Inc. | 1 | $17 |
Products named: INGREZZA, ABILIFY MAINTENA, CAPLYTA, VRAYLAR, ARISTADA, COBENFY, AUSTEDO XR, HETLIOZ.
Industry payments across NV — which companies pay providers there.
